Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
The company is stepping back in second-line breast cancer.
First-in-human study listings include EOS-215 and RO7673396.
The company’s matching strategy for CB-010 will soon be put to the test.
